1 / 28

Genetika primárnych mozgových nádorov.

Genetika primárnych mozgových nádorov. 1p / 19q status v oligodendrogliómoch MGMT status v glioblastómoch INI1 proteín v rabdoidných tumoroch. Oligodendrogliómy a 1p / 19q LOH. T1W. Oligodendrogliómy. odpoveď na PCV (1980, Levin et al.) súvis s 1p / 19q (1994, Reifenberg et al.).

kami
Download Presentation

Genetika primárnych mozgových nádorov.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Genetika primárnych mozgových nádorov.

  2. 1p / 19q status v oligodendrogliómoch • MGMT status v glioblastómoch • INI1 proteín v rabdoidných tumoroch

  3. Oligodendrogliómy a 1p / 19q LOH. T1W

  4. Oligodendrogliómy • odpoveď na PCV (1980, Levin et al.) • súvis s 1p / 19q (1994, Reifenberg et al.)

  5. Metodiky • RFLP (restriction fragment length polymorphism) • PCR based microsatellite analysis • FISH • Quantitative PCR • CGH (comparative genomic hybridisation) • MLPA (multiplex ligation-dependent probe amplification – komerčné kity)

  6. 1p strata 1p/19q v priebehu ochorenia = strata chemosenzitivity • Washington University – od 1999 • Kramáre – leto 2006

  7. Dopad na liečbu? • 1p / 19q negat, LOH 10q, PTEN mutácia, EGFR amplifikácia – PCV terapia sa neodporúča (Ino et al.)

  8. Morfológia astro - like oligo - like

  9. MGMT a multiformný glioblastóm

  10. MGMT gén – na chromozóme 10q26 • metylácia MGMT promótera – epigenetický „silencing“

  11. Metodiky: • IHC • HPLC (high-performance liquid chromatography) • MSP (metylation sensitive PCR) – aj s parafínu, ale presnejšie z kryo

  12. Dopad na kliniku: • benefit alkylačnej chemoterapie – len u tumorov s metylovaným (silenced) promóterom pre MGMT • neexistuje alternatíva liečby !!!

  13. vyššie dávky temozolomidu?

  14. Atypical teratoid / rhabdoid tumor - expresia proteínu INI1

  15. Atypical teratoid / rhabdoid tumour (AT/RT) • agresívny embryonálny CNS tumor • pôvodne popísaný ako agresívny variant Wilmsovho tumoru s rabdomyosarkomatóznymi črtami

  16. hSNF5/INI1 gén lokalizovaný na 22q11.2 – supresorový gén pre AT/RT aj periférne rabdoidy • hSNF5/INI1 kóduje INI1 proteín z rodiny chromatín remodulujúceho komplexu (SWI/SFN) – regulácia transkripcie génov • AT/RT – rabdoidné elementy nemusia byť vyjadrené, imunofenotyp vysoko variabilný

  17. INI1 proteín • komerčne dostupná protilátka od 2004 • silná korelácia molekulárnych – cytogenetických a imunohistochemických znakov • AT/RT – zablokovanie expresie • ostatné CNS tumory – zachovaná expresia

  18. Meduloblastóm

  19. Biegel JA, Kalpana G, Knudsen ES, et al.: The role of INI1 and the SWI/SNF complex in the development of rhabdoid tumors: meeting summary from the workshop on childhood atypical teratoid/rhabdoid tumors. Cancer Res 2002, 62:323-8 Diagnóza AT / RT • tumor má charakteristické morfologické a imunohistochemické črty AT/RT bez dokázanej mutácie INI1 • črty meduloblastóm / PNET s dokázanou INI 1 mutáciou

  20. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features Yong Mee Cho Jene Choi Ok-Jun Lee Hyang-Im Lee Duck Jong Han and Jae Y. Ro, pages 702–706, Pathology International, Volume 56 Issue 11 Page 702-706, November 2006

  21. 52. Loss of INI1 Expression Is Characteristic of Both Conventionaland Proximal-Type Epithelioid Sarcoma JL Hornick, P Dal Cm, COM Fletcher. Brigham and Women's Hospital. HarvardMedical School. Boston, MA.

  22. Záver: • microarray gene profilings are demonstrating that genetically-based prognosis may be more reliable than histologically-based prognosis (Nutt et al., 2003)

  23. Použitá literatúra: • 7th Congress of the European Association for Neurooncology (EANO), Postgraduate Course: Biomarkers and Therapy in Neurooncology, University Campus, Court 2, Lecture Hall CI, Spitalgasse 2, 1090 Vienna, Austria Thursday, September 14, 2006, 9.00-10.30 • MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma, Monika E. Hegi, Ph.D., Annie-Claire Diserens, M.Sc., Thierry Gorlia, M.Sc., N Engl J Med 352;10, march 10, 2005 • Allelic Losses at 1p36 and 19q13 in Gliomas: Correlation with Histologic Classification, Definition of a 150-kb Minimal Deleted Region on 1p36, and Evaluation of CAMTA1 as a Candidate Tumor Suppressor Gene, Violetta Barbashina,1 Paulo Salazar, Eric C. Holland, Marc K. Rosenblum and Marc Ladanyi, Clinical Cancer Research, Vol. 11, 1119– 1128, February 1, 2005 • Alterations of the hSNF5/INI1 Gene in Central Nervous System Atypical Teratoid/Rhabdoid Tumors and Renal and Extrarenal Rhabdoid Tumors, Jaclyn A. Biegel,2 Lu Tan, Fan Zhang, • Luanne Wainwright, Pierre Russo, and Lucy B. Rorke, Clinical Cancer Research, Vol. 8, 3461–3467, November 2002

More Related